Related references
Note: Only part of the references are listed.Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model
Yi-Fen Lu et al.
BLOOD (2012)
Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease
David A. Jacobsohn et al.
BLOOD (2011)
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
Amr R. Ibrahim et al.
BLOOD (2011)
Imatinib Is Effective in Children With Previously Untreated Chronic Myelogenous Leukemia in Early Chronic Phase: Results of the French National Phase IV Trial
Frederic Millot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium
Richard Aplenc et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Distinct Impact of Imatinib on Growth at Prepubertal and Pubertal Ages of Children with Chronic Myeloid Leukemia
Haruko Shima et al.
JOURNAL OF PEDIATRICS (2011)
The Costs and Cost-Effectiveness of Allogeneic Peripheral Blood Stem Cell Transplantation versus Bone Marrow Transplantation in Pediatric Patients with Acute Leukemia
Yu-Feng Lin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program
Hideki Muramatsu et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
Dysregulation of bone remodeling by imatinib mesylate
Kate Vandyke et al.
BLOOD (2010)
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib
David Marin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
Francois-Xavier Mahon et al.
LANCET ONCOLOGY (2010)
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Treatment of Pediatric Chronic Myeloid Leukemia in the Year 2010: Use of Tyrosine Kinase Inhibitors and Stem-Cell Transplantation
Meinolf Suttorp et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2010)
Second-Generation Tyrosine Kinase Inhibitors in the Post-Transplant Period in Patients with Chronic Myeloid Leukemia or Philadelphia-Positive Acute Lymphoblastic Leukemia
Evgeny Klyuchnikov et al.
ACTA HAEMATOLOGICA (2009)
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
Elias Jabbour et al.
BLOOD (2009)
How I monitor residual disease in chronic myeloid leukemia
Jerald P. Radich
BLOOD (2009)
Imatinib for refractory chronic graft-versus-host disease with fibrotic features
Attilio Olivieri et al.
BLOOD (2009)
Quality of life after allogeneic hematopoietic cell transplantation
Joseph Pidala et al.
BLOOD (2009)
AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
Thomas O'Hare et al.
CANCER CELL (2009)
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph plus acute leukemias
Elena Marangon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib
Hansjoerg Schmid et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Jane F. Apperley et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Allogeneic Stem Cell Transplantation for Pediatric and Adolescent Patients with CML: Results from the Prospective Trial CML-paed I
M. Suttorp et al.
KLINISCHE PADIATRIE (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
Stephanie J. Lee et al.
BLOOD (2008)
Population Pharmacokinetics and Pharmacogenetics of Imatinib in Children and Adults
Aurelie Petain et al.
CLINICAL CANCER RESEARCH (2008)
Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty
Stefania Mariani et al.
LANCET (2008)
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
Hagop Kantarjian et al.
BLOOD (2008)
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Mason Bond et al.
PEDIATRIC BLOOD & CANCER (2008)
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced intensity conditioning for patients with chronic myeloid leukemia
Partow Kebriaei et al.
BLOOD (2007)
How I treat chronic myeloid leukemia in the imatinib era
John M. Goldman
BLOOD (2007)
Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
Paul A. Carpenter et al.
BLOOD (2007)
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia
Simona Soverini et al.
CLINICAL CANCER RESEARCH (2006)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani et al.
BLOOD (2006)
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Risto Kerkela et al.
NATURE MEDICINE (2006)
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
CA Huff et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Pregnancy among patients with chronic myeloid leukemia treated with imatinib
P Ault et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation
F Millot et al.
LEUKEMIA (2006)
Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML
B Horn et al.
BONE MARROW TRANSPLANTATION (2006)
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
C Crawley et al.
BLOOD (2005)
Metabolism and disposition of imatinib mesylate in healthy volunteers
HP Gschwind et al.
DRUG METABOLISM AND DISPOSITION (2005)
Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia
F Millot et al.
PEDIATRICS (2005)
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
MA Champagne et al.
BLOOD (2004)
Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood
EA Kolb et al.
CANCER (2003)
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Stem cell transplantation for chronic myeloid leukemia in children
K Cwynarski et al.
BLOOD (2003)
Practical management of patients with chronic myeloid leukemia receiving imatinib
MWN Deininger et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
SG O'Brien et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase
R Or et al.
BLOOD (2003)
Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia
MH Gilleece et al.
LEUKEMIA & LYMPHOMA (2003)
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
F Millot et al.
BONE MARROW TRANSPLANTATION (2003)
The World Health Organization (WHO) classification of the myeloid neoplasms
JW Vardiman et al.
BLOOD (2002)
Chronic graft-versus-host disease in children: incidence, risk factors, and impact on outcome
M Zecca et al.
BLOOD (2002)
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
M Talpaz et al.
BLOOD (2002)
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation
DJ Weisdorf et al.
BLOOD (2002)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen
R Chakraverty et al.
BLOOD (2002)
Remarkably reduced transplant-related complications by dibromomannitol non-myeloablative conditioning before allogeneic bone marrow transplantation in chronic myeloid leukemia
A Barta et al.
ACTA HAEMATOLOGICA (2001)
Share Paper
